Search company, investor...
Akcelis company logo

Akcelis

akcelis.com

Founded Year

2015

Stage

Acquired | Acquired

About Akcelis

Akcelis is a patient management company that provides recruitment for clinical trials, multilingual patient surveys through the C-Lys platform, and direct-to-patient communication projects.On March 12th, 2020, Akcelis was acquired by Pivotal, terms of the transaction were not disclosed.

Headquarters Location

Nazareth, 9810,

Belgium

Missing: Akcelis's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Akcelis's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Akcelis

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Akcelis is included in 2 Expert Collections, including Telehealth.

T

Telehealth

2,854 items

Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.

D

Digital Health

13,118 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Latest Akcelis News

Pivotal acquires patient-recruitment specialist Akcelis

Mar 12, 2020

The acquired company offers an array of clinical trial patient management services, solutions around recruitment and communication Pivotal, a Madrid-based contract research organization (CRO), has purchased Akcelis, a patient-management company centered in Belgium. The acquired firm will be rebranded as “Akcelis – A Pivotal Company.” Obstacles and opportunities​ Lidia Farr, vice president of corporate development and finance at Pivotal, told Outsourcing-Pharma that recruiting patients and volunteers for trial participation is an all-too-common obstacle. “Studies have shown that 80% of the trials fail to meet planned recruitment milestones. Patient enrollment is the leading cause of missed clinical trial deadlines of which patient recruitment is the biggest contributor to such delays​,” she said. Farr added, “The success and timelines for attracting and enrolling patients in clinical trials have a direct impact on the time it takes to get a drug or medical device to the market. Delays result in higher operating costs, impatient investors, losses in sales, and other important penalties and drawbacks​.” Additionally, Farr told us, recruitment of specialized patient population presents unique challenges, especially in Europe, where trial staff face stringent regulatory challenges and cultural differences. Still, she added, opportunities abound. “There is a strong growth market for patient recruitment in Europe: the market of clinical trials grew over 35% over the last five years,” she said. “In addition, there is an increasing trend of insourcing patient recruitment capabilities by CROs in order to strengthen their service portfolio by patient centric services in this highly competitive industry.​” “The market is progressively in demand for specialized patient recruitment services as part of full-service projects (‘one-stop-shop’) conducted by CROs rather than as a stand-alone service​,” she said. Improved abilities​ Farr said Akcelis appealed to her firm because of a demonstrated record in recruiting patients and healthy for volunteers in Europe. “Akcelis offers services using a unique full-service online patient recruitment platform with a team of multilingual pharma industry experts and digital community experts​,” she said. “Fully GDPR compliant and high-quality standards have allowed Akcelis to deliver successfully several international patient recruitment projects for top 5 pharma companies, biotech companies, and medical device companies​.” Barbara D’haene and Nathalie Niclaus, Akcelis’s managing directors and founders, said the acquisition will enable Pivotal to provide current and future clients with increased service offerings, as well as a range of patient recruitment experts. “Pivotal’s expertise in clinical research and Akcelis’ patient-centric approach to accelerate patient recruitment are the winning combination for scientifically elegant and patient-friendly clinical trials​,” they said. Farr revealed to Outsourcing-Pharma that Pivotal´s three-year strategic business plan includes seeking more acquisition targets, adding that company leaders “hope to increase our service offerings across all needed area within clinical development​.” Copyright - Unless otherwise stated all contents of this web site are © 2020 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions

Akcelis Frequently Asked Questions (FAQ)

  • When was Akcelis founded?

    Akcelis was founded in 2015.

  • Where is Akcelis's headquarters?

    Akcelis's headquarters is located at Nazareth.

  • What is Akcelis's latest funding round?

    Akcelis's latest funding round is Acquired.

  • Who are the investors of Akcelis?

    Investors of Akcelis include Pivotal.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.